Viscosupplementation with high molecular weight native hyaluronan. Focus ona1500-2000 KDa fraction (Hyalubrix®)

European Review for Medical and Pharmacological Sciences

Volumn 18, Issue 21, 2014, Pages 3326-3338

  Guidolin, D ^a   Franceschi, F ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Hyaluronan; Intra articular therapy; Osteoarthritis; Vis cosupplementation; Viscoinduction

Indexed keywords

HYALURONIC ACID;

ARTHROPATHY; ARTICLE; COMPARATIVE STUDY; DEGENERATIVE JOINT ARTHROPATHY; FLOW KINETICS; FOLLOW UP; HUMAN; MOLECULAR WEIGHT; MULTICENTER STUDY (TOPIC); OSTEOARTHRITIS; PERSONAL EXPERIENCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYNOVIAL FLUID; VISCOSUPPLEMENTATION; INTRAARTICULAR DRUG ADMINISTRATION; PAIN; PROCEDURES;

HUMANS; HYALURONIC ACID; INJECTIONS, INTRA-ARTICULAR; MOLECULAR WEIGHT; OSTEOARTHRITIS; PAIN; VISCOSUPPLEMENTATION;

EID: 84941023609     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (79)

1. LAURENT TC, FRASER JRE. Hyaluronan. FASEB J 1992;6:2397-2404.
2. FRASER JRE, LAURENT TC, LAURENT UBG. Hyaluronan: Its nature, distribution, functions and turnover. J Intern Med 1997;242:27-33.
3. BALAZS EA, WATSON D, DUFF I F, ROSEMAN S. Hyaluronic acid in synovial fluid. I. Molecular parameters of hyaluronic acid in normal and arthritic human fluids. Arthritis Rheum 1967;10:357-376.
4. BOTHNER H, WIK O. Rheology of hyaluronate. Acta Otolaryngol (Stockh) 1987; Suppl 442:25-30.
5. BALAZS EA, DENLINGER JL. Sodium hyaluronate and joint function. Equine Vet Sci 1985;5:217-228.
6. CULLIS-HILL D, GHOSH P. The role of hyaluronic acid in joint stability-a hypothesis for hip displasia and allied disorders Med Hypotheses 1987;23:171-185.
7. OGSTON AG, PRESTON BN. The exclusion of protein by hyaluronic acid. Measurement by light scattering. J Biol Chem 1966;241:17-19.
8. LEVICK JR. Synovial fluid hydraulics. Sci Med 1996;3:52-62.
9. MCDONALD JN, LEVICK JR. Hyaluronan reduces fluid escape rate from rabbit knee joints disparately from its effect on fluidity. Exp Physiol 1994;79:103-106.
10. SCOTT D, COLEMAN PJ, MASON RM, LEVICK JR. Concentration-dependence of interstitial flow buffering by hyaluronan in synovial joints. Microvasc Res 2000;59:345-353.
11. FAKHARI A, BERKLAND C. Application and emerging trends of hyaluronic acid in tissue engineering, as a dermal filler and in osteoarthritis treatment. Acta Biomater 2013;9:7081-7092.
12. DAHL LB, DAHL IMS, ENGSTROM-LAURENT A, GRANATH K. Concentration and molecular weight of sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other arthropathies. Ann Rheum Dis 1985;44:817-22.
13. GREENWALD RA. Oxygen radicals, inflammation, and arthritis - pathophysiological considerations and implications for treatment. Semin Arthritis Rheum 1991;20:219-240.
14. STEPHENS RW, GHOSH P, TAYLOR TKF, GALE CA, SWANN JC, ROBINSON RG, WEBB J. The origins and relative distribution of polysaccharidases in rheumatoid and oesteoarthritic fluids. J Rheumatol 1975;2:393-400.
15. STAIR-NAWY S, CSOKA AB, STERN R. Hyaluronidase expression in human skin fibroblasts. Biochem Bio-phys Res Commun 1999;266:268-273.
16. BALAZS EA, DENLINGER JL. Viscosupplementation: A new concept in the treatment of osteoarthritis. J Rheumatol 1993;20:3-9.
17. RYDELL N, BALAZS EA. Effect of intra-articular injection of hyaluronic acid on the clinical symptoms of osteoarthritis and on granulation tissue formation. Clin Orthop 1971;80:25-32.
18. BALAZS EA, BAND P. Hyaluronic acid - its structure and use. Cosmet Toiletries 1984;99:65-72.
19. BALASZ EA. Viscosupplementation for treatment of osteoarthritis: from initial discovery to current status and results. Surg Technol Int 2004;12:278-89.
20. PEYRON JG, BALAZS EA. Preliminary clinical assessment of Na-hyaluronate injection into human arthritic joints. Pathol Biol 1974;22:731-736.
21. PEYRON JG. A new approach to the treatment of osteoarthritis: viscosupplementation. Osteoarthri-tis Cartilage 1993;1:85-87.
22. DOUGADOS M, NGUYEN M, LISTRAT V, AMOR B. High molecular weight sodium hyaluronate (hyalectin) in osteoarthritis of the knee: a 1 year placebo controlled trial. Osteoarthr Cartil 1993;1:97-103.
23. ALTMAN RD, MOSKOWITZ R. Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. Hyalgan Study Group. J Rheumatol 1998;25:2203-2212.
24. LISTRAT V, AYRAL X, PATARNELLO F, BONVARLET J P, SIMONNET J, AMOR B, DOUGADOS M. Arthroscopic evaluation of potential structure modifying activity of hyaluronan (Hyalgan) in osteoarthritis of the knee. Osteoarthr Cartil 1997;5:153-160.
25. FRIZZIERO L, GOVONI E, BACCHINI P. Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee: clinical and morphological study. Clin Exp Rheumatol 1998;16:441-449.
26. FRASER JRE, BROWN TJ, CAHILL TNP, LAURENT TC, LAURENT UBG. The turnover of hyaluronan in synovial joints (abstract). Immunol Cell Biol 1996;74:A10.
27. LAURENT UBG, FRASER JRE, ENGSTRÖM-LAURENT A, REED RK, DAHL LB, LAURENT TC. Catabolism of hyaluronan in the knee joint of the rabbit. Matrix 1992;12:130-136.
28. SAKAMOTO T, MIZONO S, MIYAZAKI K, YAMAGUCHI T, TOYOSHIMA H, NAMIKI O. Biological fate of sodium hyaluronate (SPH): Studies on the distribution, metabolism, and excretion of 14C-SPH in rabbits after intra-articular administration. Pharmacomet-rics 1984;28:375-87.
29. GHOSH P, GUIDOLIN D. Potential mechanism of action of intra-articular hyaluronan therapy in os-teoarthritis: are the effects molecular weight dependent? Semin Arthritis Rheum 2002;32:10-37.
30. LEE J Y, SPICER A P. Hyaluronan: a multifunctional, megaDalton, stealth molecule. Curr Opin Cell Biol 2000;12:581-586.
31. MORELAND LW. Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action. Arthritis Res Ther 2003;5:54-67.
32. OHKAWARA Y, TAMURA G, IWASAKI T, TANAKA A, KIKUCHI T, SHIRATO K. Activation and transforming growth factor beta production in eosinophils by hyaluro-nan. Am J Respir Cell Mol Biol 2000;23:444-451.
33. YANG C, CAO M, LIU H, HE Y, XU J, DU Y, LIU Y, WANG W, CUI L, HU J, GAO F. The high and low molecular weight forms of hyaluronan have distinct effects on CD44 clustering. J Biol Chem 2012;287:43094-43107.
34. SMITH MM, GHOSH P. The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of the hyaluronate in the extracellular environment. Rheumatol Int 1987;7:113-122.
35. GIGANTE A, CALLEGARI L. The role of intra-articular hyaluronan (Sinovial) in the treatment of os-teoarthritis. Rheumatol Int 2011;31:427-444.
36. ®). Clinical investigator's brochure. 2004; Padova: Fidia Farmaceutici SpA.
37. GIBBS D, MERRILL E, SMITH K. Rheology of hyaluronic acid. Biopolymers 1968;6:777-791.
38. MAZZUCCO D, MCKINLEY G, SCOTT RD, SPECTOR M. Rheology of joint fluid in total knee arthroplasty patients. J Orthop Res 2002;20:1157-1163.
39. YOKOBORI AT, KAWAHARADA T, SASAKI S, WATANABE S, FANG SH, KOMATSU S, HAYASHI T. Mechanical test method on the estimation of the lubricant performance by Hyaluronic Acid. Biomed Mat Eng 1995;5:117-124.
40. PASQUALI RONCHETTI I, QUAGLINO D, MORI G, BACCHELLI B, GHOSH P. Hyaluronan-phospholipid interactions. J Struct Biol 1997;120:1-10.
41. NITZAN DW, NITZAN U, DAN P, YEDGAR S. The role of hyaluronic acid in protecting surface-active phos-pholipids from lysis by exogenous phospholipase A2. Rheumatology 2001;40:336-340.
42. COLEMAN PJ, SCOTT D, MASON RM, LEVICK JR. Role of hyaluronan chain length in buffering interstitial flow across synovium in rabbits. J Physiol 2000;526. 2:425-434.
43. ASARI A, MIYAUCHI S, MATSUZAKA S, ITO T, KOMINAMI E, UCHIYAMA Y. Molecular weight-dependent effects of hyaluronate on the arthritic synovium. Arch Histol Cytol 1998;61:125-135.
44. KOMATSU S, IWATA H, NABESHIMA T. Studies on the kinetics, metabolism and re-utilization after intra-ar-ticular administration of hyaluronan to rabbits. Arzneim Forsch 1999;49:427-433.
45. FRASER JR, KIMPTON WG, PIERSCIONEK BK, CAHILL TNP. The kinetics of hyaluronan in normal and acutely inflamed synovial joints: observations with experimental arthritis in sheep. Semin Arthritis Rheum 1993;22(S1):9-17.
46. SCHIEB F. Intraartikulär injizierte Hyaluronsäure bei arthropathien. Arthritis Rheum 2003;6:338-340.
47. ®) in synovial joints with osteoarthri-tis. Eur J Phys Rehabil Med 2011;47:1-9.
48. RANZA R, MARCHESONI A, CALORI G, BIANCHI G, BRAGA M, CANAZZA S, CANESI B, FUMAGALLI M, MASTAGLIO C, MATHIEU A. The italian version of the Functional Disability Index of the Health Assessment Questionnaire. A reliable instrument for multicenter studies on rheumatoid arthritis. Clin Exp Rheuma-tol 1993;11:123-128.
49. BRUCE B, FRIES J. The Stanford health assessment questionnaire (HAQ): a review of its history, issues, progress, and documentation. J Rheumatol 2003;30:167-178.
50. INGEGNOLI F, SOLDI A, MERONI PL. Power Doppler sonography and clinical monitoring for hyaluronic acid treatment of rhizarthrosis: a pilot study. J Hand Microsurg 2011;3:51-54.
51. DI SANTE L, CACCHIO A, SCETTRI P, PAOLONI M, IOPPOLO F, SANTILLI V. Ultrasound-guided procedure for the treatment of trapeziometacarpal osteoarthritis. Clin Rheumatol 2011;30:1195-1200.
52. SMIDERLE C, SCAPIN M, BALDO M, RONCONI L, MARCOLIN G, VILLAMINAR R. Gait analysis of changes in clinical and biomechanical parameters in os-teoarthritis knee patients after intraarticular infiltration with high molecular weight hyaluronan. Eur Med Phys 2007;43:1-3.
53. SMIDERLE C, SCAPIN M, RONCONI L, BALDO M, VILLAMINAR R. Changes in clinical and biomechanical parameters in osteoarthritis knee patients after intra-articu-lar infiltration with hyaluronic acid h.m.w. In: Proceedings of the 17th annual meeting of the European Society of Movement Analysis for adults and children. Turin: Edizioni Minerva Medica, 2008.
54. GOK H, ERGIN S, YAVUZER G. Kinetic and Kinematic characteristics of gait in patients with medial knee arthrosis. Acta Orthop Scand 2002;73:647-652.
55. CHEN CPC, CHEN MJL, PEI YC, LEW HL, WONG PY, TANG SFT. Sagittal plane loading response during gait in different age groups and in people with knee osteoarthritis. Am J Phis Med Rehabil 2003;82:307-312.
56. PAOLONI M, DI SANTE L, DIMAGGIO M, BERNETTI A, MANGONE M, DI RENZO S, SANTILLI V. Kinematic and kinetic modifications in walking pattern of hip os-teoarthritis patients induced by intra-articular injections of hyaluronic acid. Clin Biomech 2012;27:661-665.
57. ®) in symptomatic osteoarthritis of the hip: a prospective cohort study. Arch Orthop Trauma Surg 2011;131:1677-1685.
58. MIGLIORE A, BELLA A, BISIGNANI M, CALDERARO M, DE AMICIS D, LOGROSCINO G, MARIOTTINI F, MORESCHINI O, MASSAFRA U, BIZZI E, LAGANÀ B, PISCITELLI P, TORMENTA S. Total hip replacement rate in a cohort of patients affected by symptomatic hip osteoarthritis following intra-articular sodium hyaluronate (MW 1500-2000 kDa). ORTOBRIX study. Clin Rheuma-tol 2012;31:1187-1196.
59. ®) injections versus local anesthetic in osteoarthritis of the hip. Arthritis Res Ther 2009;11:R183.
60. FILARDO G, KON E. PRP: more words than facts. Knee Surg Sports Traumatol Arthrosc 2012;20:1655-1656.
61. FILARDO G, KON E, DI MARTINO A, DI MATTEO B, MERLI ML, CENACCHI AR, FORNASARI PM, MARCACCI M. Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial. BMC Musculoskelet Disord 2012;13:229.
62. TEGNER Y, LYSHOLM J. Rating systems in the evaluation of knee ligament injuries. Clin Orthop 1985;198:43-49.
63. ®) in arthroscopy. Artro-scopia 2007;8:1-12.
64. HAMBURGER MI, LAKHANPAL S, MOOAR PA, OSTER D. Intra-articular hyaluronans: a review of product-specific safety profiles. Semin Arthritis Rheum 2003;32:296-309.
65. ARRICH J, PIRIBAUER F, MAD P, SCHMID D, KLAUSHOFER K, MULLNER M. Intra-articular hyaluronic acid for the treatment of the knee: systematic review and meta-analysis. CMAJ 2005;172:1039-1043.
66. CARR AJ. Beyond disability: measuring the social and personal consequences of osteoarthritis. Os-teoarthr Cartil 1999;7:230-238.
67. National Institute of Clinical Excellence. OS-TEOARTHRITIS national clinical guideline for care and management in adults. 2009; http://www.nice.org. uk/nicemedia/pdf/CG059FullGuideline.pdf. Last accessed: July 5, 2013.
68. JORDAN KM, ARDEN NK, DOHERTY M, BANNWARTH B, BIJLSMA JW, DIEPPE P, GUNTHER K, HAUSELMANN H, HERRERO-BEAUMONT G, KAKLAMANIS P, LOHMANDER S, LEEB B, LEQUESNE M, MAZIERES B, MARTIN-MOLA E, PAVELKA K, PENDLETON A, PUNZI L, SERNI U, SWOBODA B, VERBRUGGEN G, ZIMMERMAN-GORSKA I, DOUGADOS M. EULAR recommendations 2003: an evidence based approach to the management of knee os-teoarthritis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-1155.
69. ZHANG W, DOHERTY M, ARDEN N, BANNWARTH B, BIJLSMA J, GUNTHER K P, HAUSELMANN HJ, HERRERO-BEAUMONT G, JORDAN K, KAKLAMANIS P, LEEB B, LEQUESNE M, LOHMANDER S, MAZIERES B, MARTIN-MOLA E, PAVELKA K, PENDLETON A, PUNZI L, SWOBODA B, VARATOJO R, VERBRUGGEN G, ZIMMERMANN-GORSKA I, DOUGADOS M. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005;64:669-681.
70. MIGLIORE A, GIOVANNANGELI F, GRANATA M, LAGANÀ B. Hylan g-f 20: review of its safety and efficacy in the management of joint pain in osteoarthritis. Clin Med Insights Arthritis Musculoskelet Disord 2010;3:55-68.
71. MAINIL-VARLET P, SCHIAVINATO A, GANSTER MM. Efficacy evaluation of a new hyaluronan derivative HYADD 4G to maintain cartilage integrity in a rabbit model of osteoarthritis. Cartilage 2013;4:28-41.
72. BELLAMY N, CAMPBELL J, ROBINSON V, GEE T, BOURNE R, WELLS G. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006;2:CD005321.
73. BANNURU RR, NATOV NS, DASI UR, SCHMID CH, MCALINDON TE. Therapeutic trajectory following intra-articular hyaluronic acid injection in knee osteoarthritis-meta-analysis. Osteoarthri-tis Cartilage 2011;19:611-619.
74. POZO MA, BALAZS EA, BELMONTE C. Reduction of sensory responses to passive movements of inflamed knee joints by hylan, a hyaluronan derivative. Exp Brain Res 1997;116:3-9.
75. GOMIS A, MIRALLES A, SCHMIDT R F, BELMONTE C. Intra-articular injections of hyaluronan solutions of different elastoviscosity reduce nociceptive nerve activity in a model of osteoarthritic knee joint of the guinea pig. Osteoarthritis Cartilage 2009;17:798-804.
76. PASQUALI RONCHETTI I, GUERRA D, TAPARELLI F, BORALDI F, BERGAMINI G, MORI G, ZIZZI F, FRIZZIERO L. Morphological analysis of knee synovial membrane biopsies from a randomized controlled clinical study comparing the effect of sodium hyaluronate (Hyal-gan) and methylprednisolone acetate (Depome-drol) in osteoarthritis. Rheumatology 2001;40:158-169.
77. GUIDOLIN D, PASQUALI RONCHETTI I, LINI E, GUERRA D, FRIZZIERO L. Morphological analysis of articular cartilage biopsies from a randomized, clinical study comparing the effect of 500-730 kDa sodium hyaluronate (Hyalgan) and methylpred-nisolone acetate on primary osteoarthritis of the knee. Osteoarthr Cartil 2001;9:371-381.
78. DRAGOMIR CL, SCOTT JL, PERINO G, ADLER R, FEALY S, GOLDRING MB. Acute inflammation with induction of anaphylatoxin C5a and terminal complement complex C5b-9 associated with multiple intra-ar-ticular injections of hylan G-F20: a case report. Osteoarthritis Cartilage 2012;20:791-795.
79. GOLDBERG VM, COUTTS RD. Pseudoseptic reactions to hylan viscosupplementation: diagnosis and treatment. Clin Orthop Relat Res 2004;419:130-137.